Lilly reports Q3 2024 financial results highlighted by strong volume-driven revenue growth from New Products
Revenue in Q3 2024 increased 20%, driven by volume growth from Mounjaro and Zepbound, partially offset by $1.42 billion of revenue in Q3 2023 from the sale of rights for